Streetbeat News

Revenues

RKLB

Rocket Lab USA Inc (NASDAQ:RKLB) shares are trading higher after being awarded a $14.49 million launch contract by the U.S. Space Force for the Space Test Program-30 mission. The mission aims to deliver research experiments and technology demonstrations to orbit and is scheduled within 24 months. Wall Street analysts generally view RKLB as a Buy, despite a 27.55% fall in the past 3 months. The stock was up 2.37% at $3.86 at the time of publication.

Portfolio Pulse from Adam Eckert

April 09, 2024 | 1:45 pm

TCNNF

Kim Rivers, CEO of Trulieve (OTCQX:TCNNF), responded to Florida Governor Ron DeSantis's negative views on cannabis legalization, arguing that cannabis is scientifically proven to be healthier than alcohol and that its legalization in Florida would improve residents' quality of life. Trulieve has contributed $40 million to the Smart & Safe Florida campaign to support the cannabis legalization initiative, known as Amendment 3, which will be on the November 2024 ballot. If passed, this initiative could significantly expand the market for existing medical cannabis companies and increase state tax revenues.

Portfolio Pulse from Maureen Meehan

April 09, 2024 | 1:16 pm

CTVA

Analysts have mixed views on Corteva (NYSE:CTVA), with recent updates showing a mix of bullish and bearish ratings. The average 12-month price target is $61.3, reflecting a 4.89% increase from the previous target. Corteva, an agriculture company, has seen a revenue decline of -3.08% as of December 31, 2023, but maintains a strong market position with a notable net margin and ROA.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 1:01 pm

SAM

Boston Beer Co (NYSE:SAM) received mixed analyst ratings, with a recent shift towards a more bearish outlook. The latest analysis by 9 analysts shows a range of ratings from bullish to bearish, with a notable increase in bearish sentiment in the last 30 days. The average 12-month price target for SAM is $334.56, slightly up from the previous $331.33, despite recent downgrades by several analysts. Boston Beer's financial performance shows challenges in revenue growth, net margin, ROE, and ROA, although it maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 1:01 pm

AVDX

AvidXchange Holdings (NASDAQ:AVDX) was analyzed by 6 analysts, showing a shift towards a more cautious stance with 4 indifferent ratings recently. The 12-month price targets suggest optimism with an average target of $14.08, up from $12.80. The company's financials indicate a strong revenue growth of 20.76% but challenges in profitability and efficiency, with a net margin of -4.3% and ROE of -0.69%.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 1:00 pm

ALPN

Alpine Immune Sciences (NASDAQ:ALPN) has received 8 analyst ratings in the past three months, showing a bullish trend with an average 12-month price target of $46.12, marking a 38.37% increase from the previous target. Analysts from firms like Guggenheim and Morgan Stanley have adjusted their ratings and price targets, reflecting optimism about ALPN's future performance. The company's financial health is strong, with significant revenue growth, high net margin, and excellent ROE and ROA, indicating efficient management and operational capacity.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 1:00 pm

NAOV

NanoVibronix reported its Q4 2023 revenue to be approximately $1.2 million.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:56 pm

TAOP

Taoping Inc. reported an estimated Q1 2024 contract revenue of approximately $8.3 million, marking a 53% increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:54 pm

LQR

LQR House announced its March 2024 revenue of $206,221.82, marking a significant increase from the $43,578.33 reported in the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:50 pm

BCTX

BriaCell presented positive Phase 2 data for Bria-IMT™, showing promising results in ADC resistant and CNS metastatic breast cancer at AACR 2024. The data revealed a PFS of 4.2 months, double that of controls, and a clinical benefit rate of 56%. The findings also highlighted a 71% intracranial objective response rate in heavily pretreated patients, underscoring Bria-IMT™'s potential in advanced breast cancer treatment. Additionally, preclinical data for Bria-OTS+™ and Bria-PROS+™ will be presented, indicating ongoing research efforts.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:49 pm